OKYO Pharma(US:OKYO) Globenewswire·2025-10-29 11:00Core Insights - OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain and inflammatory eye diseases, with a lead investigational candidate, urcosimod [1][6]. Company Overview - OKYO Pharma is listed on NASDAQ and is dedicated to discovering and developing novel molecules for treating ocular diseases, particularly neuropathic corneal pain and dry eye disease [6]. - The company recently completed a Phase 2 clinical trial for urcosimod, which is currently being evaluated for its efficacy in treating neuropathic corneal pain [6]. Clinical Development - Urcosimod, a lipid conjugated chemerin peptide agonist, has demonstrated anti-inflammatory and pain-reducing effects in preclinical models and has shown statistical significance in multiple endpoints during a 240-patient Phase 2 trial for dry eye disease [5]. - A recent Phase 2 trial involving 17 patients with neuropathic corneal pain has just been completed, indicating progress in the clinical development of urcosimod [5][6]. Upcoming Events - The CEO of OKYO Pharma, Dr. Gary S. Jacob, will present at the 33rd Annual BIO-Europe partnering conference in Vienna, Austria, scheduled for November 3-5, 2025, where he will discuss the company's advancements and clinical milestones [2][3].